Business school cohorts may not seem like an obvious place to find individuals helping to tackle the spread of deadly infections around the world.
However, in among the usual mix of entrepreneurs and students focused on finance or operations management, one student is using their business knowledge to make a difference in global health.
Matthew Doherty is a Global Doctorate of Business Administration (G-DBA) student on the first-ever joint program offered by Durham University Business School and emlyon Business School.
Alongside his studies (he will graduate in 2021), Matthew has held full-time roles within the World Health Organization (WHO), the Medicines for Malaria Venture (MMV), and the International AIDS Society (IAS) and is currently working as part of the Global Antibiotic R&D Partnership (GARDP).
As this career history suggests, Matthew’s focus is firmly on global health and he’s used the research training gained on his G-DBA course to build a diverse knowledge base and skillet he would have found difficult to acquire elsewhere.
He said: “It has also increasingly ingrained my work with a rigorous attitude and a critical eye. Given the stringent approach to research and regulation in the health sector, such competencies are highly valued and often at a premium.”
Matthew’s roles during his career have been focused on financing, policy, strategy and communications, specifically related to innovation and access to medicines and other health products. With the current Covid-19 pandemic, his work has taken on a feeling of renewed importance.
Since its establishment in 2016, GARDP has formed more than 50 partnerships in 20 countries, building a base of knowledge and expertise, and created research platforms and programs to deliver new antibiotics.
He said: “GARDP was created to unite the public and private sectors in responding to the threat of antibiotic resistance. Our goal is to bring together vital resources and expertise to deliver new treatments for bacterial infections.
“A lot of great work has been done since GARDP was established and the ambitious plan to deliver five new treatments by 2025 - for the drug-resistant infections that pose the greatest threat worldwide - is underway.
Matthew added: “This will cost around €500m (approx. US$544m) and it is my responsibility, along with my team members, to ensure this is fully funded.”



Get closer to your dream programme
Your consent preferences have been set.
Time to start exploring.
Your account has been removed.
You can still browse the site or sign up again once you have parental consent.
Get closer to your dream programme